| 0.0415 -0.001 (-3.26%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.1  |
1-year : | 0.15 |
| Resists | First : | 0.09 |
Second : | 0.13 |
| Pivot price | 0.04  |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.04 |
MA(20) : | 0.04 |
| MA(100) : | 1.22 |
MA(250) : | 48.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 4 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 600 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCPX ] has closed above bottom band by 21.5%. Bollinger Bands are 99.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.04 - 0.04 | 0.04 - 0.04 |
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
Mon, 05 May 2025
Scorpius Slashes $6M in Costs While Pioneering Halal Biomanufacturing Hub in Southeast Asia - Stock Titan
Sun, 04 May 2025
Scorpius Holdings Announces Corporate Update Including Cost - GlobeNewswire
Wed, 30 Apr 2025
Scorpius Holdings Battles Biotech Headwinds with Major Cost-Cutting Plan as Revenue Hits $6M - Stock Titan
Wed, 30 Apr 2025
Scorpius Holdings Provides 2024 Year-End Business Update; - GlobeNewswire
Mon, 21 Apr 2025
Scorpius Holdings (SCPX) Faces Delisting from NYSE American Due to Low Stock Price | SCPX Stock News - GuruFocus
Mon, 21 Apr 2025
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.79e+006 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.498e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 144.6 % |
| Return on Equity (ttm) | -32.1 % |
| Qtrly Rev. Growth | 9.85e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -181.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 24290 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|